Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus by Wei Zhu, Wen Huang, Zhiqiang Xu, Mengda Cao, Qiaoli Hu, Chen Pan, Miao Guo, Ji-Fu Wei, Hongyu Yuan

“…Combined use of multiple antidiabetic drugs poses a risk to patients due to drug interactions and overtreatment.…”
Get full text

Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: a cross-sectional study by Maria Jose Nino-Orrego, Daniela Baracaldo-Santamaría, Claudia Patricia Ortiz, Heyde Patricia Zuluaga, Sthefany Alejandra Cruz-Becerra, Franklin Soler, Andrés M. Pérez-Acosta, Daniel Ricardo Delgado, Carlos-Alberto Calderon-Ospina

“…Given the massive release of misleading information during the pandemic, some pharmacies recommend drugs such as ivermectin, azithromycin, and hydroxychloroquine that are not useful for preventing or treating COVID-19 and could expose patients to unnecessary adverse drug reactions (ADRs), drug-drug interactions (DDIs), disease masking, and antibiotic resistance. …”
Get full text

Associations between CES1 variants and dosing and adverse effects in children taking methylphenidate by Jacob T. Brown, Nancy Beery, Allise Taran, Tyler Stevens, Christine Henzler, Jonathan Badalamenti, Ron Regal, Catherine A. McCarty

“…Variability in response and occurrence of adverse events with methylphenidate use may be due to several factors, including drug-drug interactions as well as pharmacogenetic differences resulting in pharmacokinetic and/or pharmacodynamic variances within the general population. …”
Get full text

Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies... by Sharon Walmsley, Don E. Smith, Miguel Górgolas, Pedro E. Cahn, Thomas Lutz, Karine Lacombe, Princy N. Kumar, Brian Wynne, Richard Grove, Gilda Bontempo, Riya Moodley, Chinyere Okoli, Michelle Kisare, Bryn Jones, Andrew Clark, Mounir Ait-Khaled

“…Abstract Background As the population of people with HIV ages, concerns over managing age-related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while maintaining viral suppression have arisen. …”
Get full text

Evaluación del uso de los inhibidores de la bomba de protones en un servicio de medicina interna Assessing the use of proton pump inhibitors in an internal medicine department by E. Martín-Echevarría, A. Pereira Juliá, M. Torralba, G. Arriola Pereda, P. Martín Dávila, J. Mateos, M. Rodríguez Zapata

“…Conclusions: results are in accordance with the literature, with a high frequency of incorrect PPI use; a more accurate use of PPIs is to be recommended to avoid side effects and drug interactions, and to provide a more efficient medical care.…”
Get full text

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. by Lufina Tsirizani Galileya, Roeland E Wasmann, Chishala Chabala, Helena Rabie, Janice Lee, Irene Njahira Mukui, Anneke Hesseling, Heather Zar, Rob Aarnoutse, Anna Turkova, Diana Gibb, Mark F Cotton, Helen McIlleron, Paolo Denti

“…The importance of the drug-drug interactions with lopinavir/ritonavir and efavirenz should be evaluated further and considered in future dosing guidance.…”
Get full text

Clinical course and approaches to therapy in kidney transplant recipients with the novel COVID-19 disease by O. N. Kotenko, L. Yu. Artyukhina, N. F. Frolova, E. S. Stolyarevich

“…Difficulties in the management of recipients with COVID-19 are also down to the limitation of the use of drugs due to adverse drug-drug interactions. Objective: to analyze the course of COVID-19 disease in organ recipients, to assess the factors influencing the prognosis of the disease, and to optimize approaches to treatment of these patients. …”
Get full text

Engineered microtissue platforms for modeling human pathophysiology and drug metabolism by Li, Cheri Yingjie

Get full text

Drug utilization review among geriatric patients at primary care setting / Saidatul Sheeda Ahmad Shukri by Ahmad Shukri, Saidatul Sheeda

“…Changes in both pharmacokinetics and pharmacodynamics is more pronounced in patients exposed to multiple diseases, multiple drugs consumption, polypharmacy, adverse drug reactions (ADRs), drug-drug interactions, noncompliance and potentially inappropriate medications (PIMs), which contribute to the reasons for hospitalisation. …”
Get full text

The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV by Ahn, Mi Young, Jiamsakul, Awachana, Khusuwan, Suwimon, Khol, Vohith, Pham, Thuy T., Chaiwarith, Romanee, Avihingsanon, Anchalee, Kumarasamy, Nagalingeswaran, Wong, Wing Wei, Kiertiburanakul, Sasisopin, Pujari, Sanjay, Nguyen, Kinh V., Lee, Man Po, Kamarulzaman, Adeeba, Zhang, Fujie, Ditangco, Rossana, Merati, Tuti P., Yunihastuti, Evy, Ng, Oon Tek, Sim, Benedict L.H., Tanuma, Junko, Ratanasuwan, Winai, Ross, Jeremy, Choi, Jun Yong

“…Introduction: Multiple comorbidities among HIV-positive individuals may increase the potential for polypharmacy causing drug-to-drug interactions and older individuals with comorbidities, particularly those with cognitive impairment, may have difficulty in adhering to complex medications. …”

An Insight into the Metabolism of 2,5-Disubstituted Monotetrazole Bearing Bisphenol Structures: Emerging Bisphenol A Structural Congeners by Umesh B. Gadgoli, Yelekere C. Sunil Kumar, Deepak Kumar

“…The present study demonstrated that the 223-2 ligand did not elicit any significant adverse effect via metabolic activation, thus paving the way for its in vivo drug–drug interactions (DDI) studies.…”
Get full text

Nevirapine in HIV maintenance therapy – can “old drugs” survive in current HIV management? by Julia Notter, Andrea Bregenzer, Pietro Vernazza, Christian R. Kahlert

“…In HCV co-infected patients, the treatment stop rate was 4-fold higher than in HIV mono-infected patients, but this difference was mainly due to treatment interruptions caused by drug-drug interactions with intermittent HCV therapy. Six out of seven Asian patients experienced HSR (hepatotoxicity / skin rash). …”
Get full text

Underdiagnosed CKD in Geriatric Trauma Patients and Potent Prevention of Renal Impairment from Polypharmacy Risks through Individual Pharmacotherapy Management (IPM-III) by Ursula Wolf, Hassan Ghadir, Luise Drewas, Rüdiger Neef

“…Because from the expertise of more than 58,600 self-reviewed medications, adverse drug reactions, drug interactions, inadequate dosing, and contraindications all proved to cause or exacerbate the worsening of renal function, we analyzed the association of an electronic patient record- and Summaries of Product Characteristics (SmPCs)-based comprehensive individual pharmacotherapy management (IPM) in the setting of 14 daily interdisciplinary patient visits with the outcome: further renal impairment with reduction of eGFR ≥ 20 mL/min (redGFR) in hospitalized trauma patients ≥ 70 years of age. …”
Get full text

Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors by Yue Li, Hong-Li Guo, Yuan-Yuan Zhang, Na Dong, Ya-Hui Hu, Jing chen, Xiao-Peng Lu, Feng Chen

“…Children with higher BW and older age have lower C0/Dose ratio. Complex drug interactions between LCM and other concomitant ASMs were revealed. …”
Get full text

Interprofessional Collaboration between ICU Physicians, Staff Nurses, and Hospital Pharmacists Optimizes Antimicrobial Treatment and Improves Quality of Care and Economic Outcome by Stephan Schmid, Sophie Schlosser, Karsten Gülow, Vlad Pavel, Martina Müller, Alexander Kratzer

“…The suggestions of the hospital pharmacist for optimization can be divided into the following categories (i) indication for and selection of therapy (43.6%), (ii) optimization of dosing (27.6%), (iii) drug interactions (9.4%), (iv) side effects (4.1%), and (v) other pharmacokinetic, pharmacodynamic, and pharmacoeconomic topics (15.3%). …”
Get full text

Psychiatric and non-psychiatric polypharmacy among older adults with schizophrenia: Trends from a population-based study between 2000 and 2016 by Carlotta Lunghi, Carlotta Lunghi, Carlotta Lunghi, Carlotta Lunghi, Louis Rochette, Victoria Massamba, Isabelle Tardif, Amina Ouali, Caroline Sirois, Caroline Sirois, Caroline Sirois, Caroline Sirois

“…This raises concerns about the growing risks for adverse effects and drug-drug interactions in this vulnerable population.…”
Get full text

Interfacing DNA nanodevices with biology: challenges, solutions and perspectives by Mathias Vinther, Jørgen Kjems

“…One of the leading proposals of use for DNA nanotechnology has been in biology and biomedicine acting as a molecular ‘nanorobot’ or smart drug interacting with the cellular machinery. In this review, we will explore and examine the perspective of DNA nanotechnology for such use. …”
Get full text

Full spectrum cannabidiol-rich extract reduced propofol dosage required for anesthetic induction in dogs—a pilot study by João Lourenço Hasckel Gewehr, Maria Laura Enzele, Lucas Marlon Freiria, Morgana Martins Nunes, Júlia Spengler, Ana Paula Dondoerfer Teixeira, Erik Amazonas, Erik Amazonas, Vanessa Sasso Padilha

“…Additionally, further research is needed to determine the best dosage, delivery method, time for administration, ideal molecular profile for desired effects, safety, drug–drug interactions, and transurgical effects.…”
Get full text

A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the ef... by E. P. Sharapova, L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, S. G. Anikin, E. A. Strebkova, A. M. Lila, V. I. Mazurov, N. A. Shostak, E. I. Shmidt, E. P. Ilivanova

“…Irrational treatment of OA in the presence of comorbidity and without considering characteristics of drug interactions leads to a pronounced increase in the number of adverse reactions (ARs) and to aggravation of the course of all concomitant diseases. …”
Get full text

Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: <i>N</i>-Functionalization Determines the Multitarget Anti-Alzheimer’s Activity Profile by Galina F. Makhaeva, Nadezhda V. Kovaleva, Natalia P. Boltneva, Elena V. Rudakova, Sofya V. Lushchekina, Tatiana Yu. Astakhova, Igor V. Serkov, Alexey N. Proshin, Eugene V. Radchenko, Vladimir A. Palyulin, Jan Korabecny, Ondrej Soukup, Sergey O. Bachurin, Rudy J. Richardson

“…These new agents displayed negligible carboxylesterase inhibition, suggesting a probable lack of untoward drug–drug interactions arising from hydrolytic biotransformation. …”
Get full text